

# John H Griffin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4455597/publications.pdf>

Version: 2024-02-01

384  
papers

20,557  
citations

9264

74  
h-index

14208

128  
g-index

388  
all docs

388  
docs citations

388  
times ranked

11936  
citing authors

#	ARTICLE	IF	CITATIONS
1	Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	12
2	Activated Protein C Strengthens Cardiac Tolerance to Ischemic Insults in Aging. <i>Circulation Research</i> , 2022, 130, 252-272.	4.5	11
3	Skeletal muscle myosin promotes coagulation by binding factor XI via its A3 domain and enhancing thrombin-induced factor XI activation. <i>Journal of Biological Chemistry</i> , 2022, 298, 101567.	3.4	6
4	3K3A-Activated Protein C Protects the Blood-Brain Barrier and Neurons From Accelerated Ischemic Injury Caused by Pericyte Deficiency in Mice. <i>Frontiers in Neuroscience</i> , 2022, 16, 841916.	2.8	8
5	Full-length plasma skeletal muscle myosin isoform deficiency is associated with coagulopathy in acutely injured patients. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1385-1389.	3.8	3
6	An optimized method for the isolation of urinary extracellular vesicles for molecular phenotyping: detection of biomarkers for radiation exposure. <i>Journal of Translational Medicine</i> , 2022, 20, 199.	4.4	4
7	EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia. <i>JCI Insight</i> , 2022, 7, .	5.0	3
8	Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 7-19.	3.8	7
9	Activated protein C and PAR1-derived and PAR3-derived peptides are anti-inflammatory by suppressing macrophage NLRP3 inflammasomes. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 269-280.	3.8	10
10	Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombin-dependent anticoagulant activity. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 470-477.	3.8	1
11	Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently. <i>Circulation Research</i> , 2021, 128, 513-529.	4.5	26
12	Activated Protein C (APC) and 3K3A-APC-Induced Regression of Choroidal Neovascularization (CNV) Is Accompanied by Vascular Endothelial Growth Factor (VEGF) Reduction. <i>Biomolecules</i> , 2021, 11, 358.	4.0	5
13	PAR1 regulation of CXCL1 expression and neutrophil recruitment to the lung in mice infected with influenza A virus. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1103-1111.	3.8	11
14	Addendum: American College of Medical Genetics consensus statement on factor V Leiden mutation testing. <i>Genetics in Medicine</i> , 2021, 23, 2463.	2.4	5
15	Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation. <i>Frontiers in Neurology</i> , 2021, 12, 593582.	2.4	11
16	Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids. <i>Blood</i> , 2021, 137, 1839-1842.	1.4	2
17	Sex-dependent effects of genetic upregulation of activated protein C on delayed effects of acute radiation exposure in the mouse heart, small intestine, and skin. <i>PLoS ONE</i> , 2021, 16, e0252142.	2.5	10
18	Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect. <i>Blood</i> , 2021, 137, 3428-3442.	1.4	18

#	ARTICLE	IF	CITATIONS
19	Skeletal Muscle Myosin Is Procoagulant By Binding Factor XI Via Its A3 Domain and Enhancing Factor XI Activation By Thrombin. <i>Blood</i> , 2021, 138, 441-441.	1.4	0
20	Sars-Cov-2 Infection Promotes Endothelial Dysfunction and Thrombosis in a Mouse Model of COVID-19. <i>Blood</i> , 2021, 138, 999-999.	1.4	1
21	Activated protein C anticoagulant activity is enhanced by skeletal muscle myosin. <i>Haematologica</i> , 2020, 105, e424-e427.	3.5	5
22	An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms. <i>Blood Advances</i> , 2020, 4, 3716-3727.	5.2	5
23	COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 506-509.	2.3	22
24	FVIIa (Factor VIIa) Induces Biased Cytoprotective Signaling in Mice Through the Cleavage of PAR (Protease-Activated Receptor)-1 at Canonical Arg41 (Arginine41) Site. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1275-1288.	2.4	21
25	3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase. <i>Stroke</i> , 2020, 51, 2236-2239.	2.0	1
26	C-terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1027-1038.	3.8	4
27	Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 901-913.	2.4	7
28	Serum amyloid A4 is a procoagulant apolipoprotein that it is elevated in venous thrombosis patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 217-223.	2.3	3
29	Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis Progression by Enhancing Vascular Integrity and Suppressing Microglial Activation. <i>Frontiers in Neuroscience</i> , 2020, 14, 333.	2.8	19
30	Plasma skeletal muscle myosin phenotypes identified by immunoblotting are associated with pulmonary embolism occurrence in young adults. <i>Thrombosis Research</i> , 2020, 189, 88-92.	1.7	4
31	Novel exomic rare variants associated with venous thrombosis. <i>British Journal of Haematology</i> , 2020, 190, 783-786.	2.5	13
32	Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus. <i>Blood</i> , 2020, 135, 1969-1982.	1.4	17
33	Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells. <i>Blood</i> , 2019, 134, 776-781.	1.4	12
34	Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis. <i>Blood</i> , 2019, 134, 1119-1131.	1.4	45
35	Neuroprotection and vasculoprotection using genetically targeted protease-ligands. <i>Brain Research</i> , 2019, 1715, 13-20.	2.2	4
36	Molecular interaction site on procoagulant myosin for factor Xa-dependent prothrombin activation. <i>Journal of Biological Chemistry</i> , 2019, 294, 15176-15181.	3.4	10

#	ARTICLE	IF	CITATIONS
37	Cardiac and Skeletal Muscle Myosin Exert Procoagulant Effects. <i>Shock</i> , 2019, 52, 554-555.	2.1	11
38	Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. <i>Annals of Neurology</i> , 2019, 85, 125-136.	5.3	113
39	3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice. <i>Journal of Experimental Medicine</i> , 2019, 216, 279-293.	8.5	55
40	Molecular Interaction Site on Procoagulant Skeletal Muscle Myosin for Factor Xa-Dependent Prothrombin Activation. <i>Blood</i> , 2019, 134, 3622-3622.	1.4	1
41	Factor VIIa Induces Biased Cytoprotective Signaling through the Cleavage of Protease Activated Receptor 1 at Canonical Arg41 Site. <i>Blood</i> , 2019, 134, 481-481.	1.4	0
42	Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo. <i>Blood</i> , 2019, 134, 3632-3632.	1.4	0
43	$\hat{I}\pm 2$ -Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC: $\hat{I}\pm 2$ M Levels Are Associated with Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2018, 47, 630-638.	3.4	13
44	SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1586-1594.	3.0	18
45	Regulation of immune cell signaling by activated protein C. <i>Journal of Leukocyte Biology</i> , 2018, 103, 1197-1203.	3.3	14
46	The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia. <i>Stem Cells</i> , 2018, 36, 796-806.	3.2	24
47	PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. <i>Blood</i> , 2018, 131, 1163-1171.	1.4	81
48	Targeting anticoagulant protein S to improve hemostasis in hemophilia. <i>Blood</i> , 2018, 131, 1360-1371.	1.4	57
49	Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C. <i>Neuropharmacology</i> , 2018, 134, 293-301.	4.1	15
50	Design of a DNA-Programmed Plasminogen Activator. <i>Journal of the American Chemical Society</i> , 2018, 140, 15516-15524.	13.7	27
51	Activated protein C, protease activated receptor 1, and neuroprotection. <i>Blood</i> , 2018, 132, 159-169.	1.4	94
52	Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo. <i>Journal of Biological Chemistry</i> , 2017, 292, 8616-8629.	3.4	84
53	Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition. <i>Blood</i> , 2017, 130, 2664-2677.	1.4	125
54	Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 33-40.	2.3	7

#	ARTICLE	IF	CITATIONS
55	Minor plasma lipids modulate clotting factor activities and may affect thrombosis risk. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 93-102.	2.3	14
56	Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S. <i>Blood Advances</i> , 2017, 1, 1423-1426.	5.2	3
57	Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa. <i>Thrombosis and Haemostasis</i> , 2016, 115, 551-561.	3.4	21
58	Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 1159-1167.	2.0	13
59	Activation-resistant homozygous protein C R229W mutation causing familial perinatal intracranial hemorrhage and delayed onset of thrombosis. <i>Thrombosis Research</i> , 2016, 143, 17-21.	1.7	2
60	Activated protein C promotes neuroprotection: mechanisms and translation to the clinic. <i>Thrombosis Research</i> , 2016, 141, S62-S64.	1.7	33
61	Physiological cerebrovascular remodeling in response to chronic mild hypoxia: A role for activated protein C. <i>Experimental Neurology</i> , 2016, 283, 396-403.	4.1	8
62	Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. <i>Blood</i> , 2016, 128, 1870-1878.	1.4	34
63	3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice. <i>Nature Medicine</i> , 2016, 22, 1050-1055.	30.7	88
64	2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2143-2151.	2.4	32
65	Safety, Stability and Pharmacokinetic Properties of superFactor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding. <i>Pharmaceutical Research</i> , 2016, 33, 1517-1526.	3.5	18
66	Apolipoprotein E Receptor 2 Mediates Activated Protein C-Induced Endothelial Akt Activation and Endothelial Barrier Stabilization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 518-524.	2.4	31
67	Activated Protein C (APC) Therapy Ameliorates Chronic Graft Versus Host Disease By Cell Signaling Mechanisms That Require Cleavage at Arg46 in PAR1 on T Cells. <i>Blood</i> , 2016, 128, 808-808.	1.4	0
68	Blocking Protein S Improves Hemostasis in Hemophilia a and B. <i>Blood</i> , 2016, 128, 79-79.	1.4	1
69	Novel R41Q- and R46Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for In Vivo Protective Mechanisms of Action for Activated Protein C (APC) in Sepsis and Stroke. <i>Blood</i> , 2016, 128, 13-13.	1.4	1
70	Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data. <i>Blood</i> , 2015, 126, 1595-1600.	1.4	49
71	Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. <i>Blood</i> , 2015, 126, 2415-2423.	1.4	28
72	EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice. <i>Blood</i> , 2015, 125, 2845-2854.	1.4	65

#	ARTICLE	IF	CITATIONS
73	Activated protein C: biased for translation. <i>Blood</i> , 2015, 125, 2898-2907.	1.4	212
74	Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation. <i>Blood</i> , 2015, 126, 2247-2253.	1.4	27
75	Arteriovenous Blood Metabolomics: A Readout of Intra-Tissue Metabostasis. <i>Scientific Reports</i> , 2015, 5, 12757.	3.3	62
76	Inhibition of thrombin generation in human plasma by phospholipid transfer protein. <i>Thrombosis Journal</i> , 2015, 13, 24.	2.1	6
77	Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 344.	3.7	20
78	Lyso-Sulfatide Binds Factor Xa and Inhibits Thrombin Generation by the Prothrombinase Complex. <i>PLoS ONE</i> , 2015, 10, e0135025.	2.5	4
79	Re-Evaluation of the Anticoagulant Properties of High-Density Lipoproteinâ€”Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 570-572.	2.4	11
80	Exome Genotyping Links Venous Thrombosis Risk with the Skeletal Muscle Myosin Gene Cluster and Leads to Discovery of New Family of Procoagulant Factors. <i>Blood</i> , 2015, 126, 763-763.	1.4	2
81	Coagulation Factor V Mediates Inhibition of Tissue Factor Signaling By Activated Protein C. <i>Blood</i> , 2015, 126, 216-216.	1.4	0
82	Role of Protein S and Gas6 in the Development of Purpura Fulminans. <i>Blood</i> , 2015, 126, 1042-1042.	1.4	0
83	Plasma Constitutive Serum Amyloid A4 Is Procoagulant and Is Elevated in Venous Thrombosis Patients. <i>Blood</i> , 2015, 126, 3486-3486.	1.4	0
84	An Engineered Factor Va Prevents Bleeding Induced by Anticoagulant wt Activated Protein C. <i>PLoS ONE</i> , 2014, 9, e104304.	2.5	17
85	Bloodâ€™spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1035-42.	7.1	188
86	Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 363-372.	3.8	29
87	Gain in translation: heme oxygenase-1 induced by activated protein C promotes thrombus resolution. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 90-92.	3.8	1
88	Warfarin untargeted metabolomics study identifies novel procoagulant ethanolamide plasma lipids. <i>British Journal of Haematology</i> , 2014, 165, 409-412.	2.5	8
89	Cytoprotective-selective activated protein C therapy for ischaemic stroke. <i>Thrombosis and Haemostasis</i> , 2014, 112, 883-892.	3.4	43
90	Synergistic Effect in Bleed Reduction By superfva and Recombinant Human FVIIa in Vivo Suggests a Novel Bypassing Strategy for Hemophilia Patients with Inhibitors. <i>Blood</i> , 2014, 124, 692-692.	1.4	2

#	ARTICLE	IF	CITATIONS
91	Reversal of Novel Oral Anticoagulant (NOAC)-Induced Bleeding in Mice By Engineered superfactor Va. Blood, 2014, 124, 695-695.	1.4	4
92	Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers. Current Pharmaceutical Design, 2014, 19, 7479-7485.	1.9	61
93	Novel R41Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for in Vivo Mechanisms of Action for Thrombin (IIa) and Activated Protein C (APC). Blood, 2014, 124, 99-99.	1.4	0
94	Acylcarnitines Are Novel Anticoagulant Lipids That Target Factor Xa and That Are Reduced in Plasma of Venous Thrombosis Patients Based on Untargeted and Targeted Metabolomics. Blood, 2014, 124, 2797-2797.	1.4	0
95	Antibody SPC-54 provides acute in vivo blockage of the murine protein C system. Blood Cells, Molecules, and Diseases, 2013, 50, 252-258.	1.4	5
96	Removal of Coagulation Factors by the Gamunex <sup>®</sup> -C Purification Process. Journal of Allergy and Clinical Immunology, 2013, 131, AB10.	2.9	3
97	Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. Brain Research, 2013, 1507, 97-104.	2.2	25
98	Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice. Blood Cells, Molecules, and Diseases, 2013, 51, 104-108.	1.4	9
99	An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR <sub>1</sub> -Akt Pathway. Journal of Neuroscience, 2013, 33, 6181-6190.	3.6	54
100	Organ-Specific Protection Against Lipopolysaccharide-Induced Vascular Leak Is Dependent on the Endothelial Protein C Receptor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 769-776.	2.4	36
101	Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats. Stroke, 2013, 44, 3529-3536.	2.0	56
102	Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity. Journal of Thrombosis and Haemostasis, 2013, 11, 2059-2062.	3.8	7
103	Elevated serum amyloid A is associated with venous thromboembolism. Thrombosis and Haemostasis, 2013, 109, 358-359.	3.4	15
104	Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation. Thrombosis and Haemostasis, 2013, 110, 275-282.	3.4	6
105	An Engineered Factor Fva Prevents Bleeding Induced By Anticoagulant Wild Type Activated Protein C. Blood, 2013, 122, 203-203.	1.4	0
106	Reduction Of Histone H1 Cytotoxicity By Activated Protein C and Its Exosite Variants. Blood, 2013, 122, 2334-2334.	1.4	1
107	Activation-Resistant Homozygous Protein C R229W Mutation Causing Familial Perinatal Intracranial Hemorrhage. Blood, 2013, 122, 3587-3587.	1.4	0
108	Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke. Current Pharmaceutical Design, 2012, 18, 4215-4222.	1.9	50

#	ARTICLE	IF	CITATIONS
109	Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. <i>Blood</i> , 2012, 120, 5237-5246.	1.4	191
110	Incorporation of Disulfide Containing Protein Modules into Multivalent Antigenic Conjugates: Generation of Antibodies against the Thrombin-Sensitive Region of Murine Protein S. <i>Journal of the American Chemical Society</i> , 2012, 134, 19318-19321.	13.7	11
111	Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2012, 129, 502-507.	1.7	3
112	An Activated Protein C Analog With Reduced Anticoagulant Activity Extends the Therapeutic Window of Tissue Plasminogen Activator for Ischemic Stroke in Rodents. <i>Stroke</i> , 2012, 43, 2444-2449.	2.0	65
113	Infrared fluorescence for vascular barrier breach in vivo – A novel method for quantitation of albumin efflux. <i>Thrombosis and Haemostasis</i> , 2012, 108, 981-991.	3.4	7
114	Protein C anticoagulant and cytoprotective pathways. <i>International Journal of Hematology</i> , 2012, 95, 333-345.	1.6	110
115	Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. <i>Nature Medicine</i> , 2012, 18, 1123-1129.	30.7	97
116	Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. <i>Blood</i> , 2012, 119, 874-883.	1.4	106
117	Factor V Inhibits PAR2-Mediated Lethal Inflammation. <i>Blood</i> , 2012, 120, 3360-3360.	1.4	4
118	In Vitro and in Vivo Neutralization of Murine Activated Protein C. <i>Blood</i> , 2012, 120, 3364-3364.	1.4	0
119	Protection Against Vascular Leakage in Vivo by a Peptide Mimetic of the Novel Tethered Ligand Generated by Non-Canonical Cleavage of Protease Activated Receptor 1 by Activated Protein C. <i>Blood</i> , 2012, 120, 497-497.	1.4	0
120	Activated Protein C Cytoprotective Signaling in Endothelial Cells Involves apoER2 and Disabled-1. <i>Blood</i> , 2012, 120, 1102-1102.	1.4	0
121	Superior in Vivo Hemostatic Properties of an Engineered Factor Va Variant for Hemophilia Mice. <i>Blood</i> , 2012, 120, 17-17.	1.4	1
122	Cytoprotective protein C pathways and implications for stroke and neurological disorders. <i>Trends in Neurosciences</i> , 2011, 34, 198-209.	8.6	129
123	Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. <i>Molecular Neurodegeneration</i> , 2011, 6, 13.	10.8	27
124	Acylideneoxindoles: A new class of reversible inhibitors of human transglutaminase 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2692-2696.	2.2	58
125	Identification of new inhibitors of protein kinase R guided by statistical modeling. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4108-4114.	2.2	18
126	Cytoprotective-Selective Activated Protein C Attenuates <i>Pseudomonas aeruginosa</i> -Induced Lung Injury in Mice. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 632-641.	2.9	37

#	ARTICLE	IF	CITATIONS
127	Human Thrombomodulin Knock-In Mice Reveal Differential Effects of Human Thrombomodulin on Thrombosis and Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2509-2517.	2.4	11
128	Plasma High Density Lipoprotein and Anticoagulant Response to Activated Protein C (APC) and Protein S. <i>Blood</i> , 2011, 118, 2249-2249.	1.4	1
129	Non-Canonical Cleavage of Protease Activated Receptor 1 (PAR1) by Activated Protein C Provides Novel Insights Into the Repertoire of Cytoprotective and Proinflammatory PAR1 Signaling. <i>Blood</i> , 2011, 118, 534-534.	1.4	1
130	Activated Protein C Cellular Pathways Regulating Thrombosis. <i>Blood</i> , 2011, 118, SCI-44-SCI-44.	1.4	0
131	Insight in Protein S Deficiency From Mouse Models. <i>Blood</i> , 2011, 118, 529-529.	1.4	7
132	Warfarin Untargeted Metabolomics Study Identifies Novel Procoagulant Ethanolamide Lipids. <i>Blood</i> , 2011, 118, 1200-1200.	1.4	1
133	Factor V Is an Anticoagulant Cofactor for Activated Protein C during Inactivation of Factor Va. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2010, 37, 17-23.	0.3	22
134	Protein S Protects Neurons from Excitotoxic Injury by Activating the TAM Receptor Tyro3â€“Phosphatidylinositol 3-Kinaseâ€“Akt Pathway through Its Sex Hormone-Binding Globulin-Like Region. <i>Journal of Neuroscience</i> , 2010, 30, 15521-15534.	3.6	57
135	Association of Apo(a) isoform size with dyslipoproteinemia in male Venous Thrombosis patients. <i>Clinica Chimica Acta</i> , 2010, 411, 1279-1283.	1.1	7
136	Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 3167-3178.	8.2	84
137	Lyso-Sulfatide Binds Factor Xa and Potently Inhibits Thrombin Generation.. <i>Blood</i> , 2010, 116, 1130-1130.	1.4	0
138	Plasma Serum Amyloid A Levels Are Increased In Venous Thrombosis Patients and Are Correlated with Blood Coagulability. <i>Blood</i> , 2010, 116, 155-155.	1.4	1
139	Novel Infrared Fluorescence Methodology Defines An Essential Role for Endothelial Protein C Receptor (EPCR) for Protection Against Vascular Leakage In Inflammation. <i>Blood</i> , 2010, 116, 653-653.	1.4	4
140	Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. <i>Thrombosis and Haemostasis</i> , 2009, 101, 724-733.	3.4	69
141	Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 274-279.	7.1	130
142	Species-specific anticoagulant and mitogenic activities of murine protein S. <i>Haematologica</i> , 2009, 94, 1721-1731.	3.5	19
143	Plasma protein S contains zinc essential for efficient activated protein Câ€“independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor. <i>FASEB Journal</i> , 2009, 23, 2244-2253.	0.5	36
144	Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. <i>European Journal of Neuroscience</i> , 2009, 29, 1119-1130.	2.6	83

#	ARTICLE	IF	CITATIONS
145	Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. <i>Journal of Neurochemistry</i> , 2009, 109, 116-124.	3.9	33
146	Human plasma phospholipid transfer protein specific activity is correlated with HDL size: Implications for lipoprotein physiology. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 206-211.	2.4	21
147	Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. <i>Journal of Clinical Investigation</i> , 2009, 119, 3437-49.	8.2	158
148	Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. <i>Blood</i> , 2009, 113, 2859-2866.	1.4	108
149	Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. <i>Blood</i> , 2009, 113, 5970-5978.	1.4	68
150	Generation and phenotypic analysis of protein S-deficient mice. <i>Blood</i> , 2009, 114, 2307-2314.	1.4	67
151	Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C. <i>Thrombosis and Haemostasis</i> , 2009, 101, 55-61.	3.4	11
152	Activated Protein C Promotes Neovascularization and Neurogenesis in Postischemic Brain via Protease-Activated Receptor 1. <i>Journal of Neuroscience</i> , 2008, 28, 12788-12797.	3.6	104
153	The Thrombin-sensitive Region of Protein S Mediates Phospholipid-dependent Interaction with Factor Xa*. <i>Journal of Biological Chemistry</i> , 2008, 283, 33046-33052.	3.4	15
154	Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry. <i>Thrombosis and Haemostasis</i> , 2008, 99, 453-455.	3.4	26
155	Elevated plasma fibronectin levels associated with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2008, 100, 224-228.	3.4	16
156	Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2). <i>Blood</i> , 2008, 112, 695-695.	1.4	0
157	Factor V as Anticoagulant Cofactor for Activated Protein C in Factor Va Inactivation. <i>Blood</i> , 2008, 112, 3075-3075.	1.4	1
158	Elevated plasma fibronectin levels associated with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2008, 100, 224-8.	3.4	4
159	Activated Protein C Mutant with Minimal Anticoagulant Activity, Normal Cytoprotective Activity, and Preservation of Thrombin Activable Fibrinolysis Inhibitor-dependent Cytoprotective Functions. <i>Journal of Biological Chemistry</i> , 2007, 282, 33022-33033.	3.4	106
160	Endotoxemia and sepsis mortality reduction by non-anticoagulant-activated protein C. <i>Journal of Experimental Medicine</i> , 2007, 204, 2439-2448.	8.5	319
161	High-Density Lipoprotein and the Risk of Recurrent Venous Thromboembolism. <i>Circulation</i> , 2007, 115, 1609-1614.	1.6	102
162	Characterization of a Factor Xa Binding Site on Factor Va near the Arg-506 Activated Protein C Cleavage Site. <i>Journal of Biological Chemistry</i> , 2007, 282, 21848-21855.	3.4	25

#	ARTICLE	IF	CITATIONS
163	Factor Va Residues 311-325 Represent an Activated Protein C Binding Region. <i>Journal of Biological Chemistry</i> , 2007, 282, 28353-28361.	3.4	12
164	Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. <i>Blood</i> , 2007, 109, 3733-3740.	1.4	49
165	The cytoprotective protein C pathway. <i>Blood</i> , 2007, 109, 3161-3172.	1.4	714
166	Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 102-108.	3.8	49
167	Activated protein C. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 73-80.	3.8	202
168	Activation of protein C and hemodynamic recovery after coronary artery bypass surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 133, 44-51.	0.8	15
169	Plasma cholesteryl ester transfer protein and blood coagulability. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1160-1164.	3.4	12
170	In Vivo Anti-Thrombotic Potency of Engineered Activated Protein C Variants.. <i>Blood</i> , 2007, 110, 2704-2704.	1.4	2
171	Preservation of Beneficial TAFI Functions by an Activated Protein C Variant with Normal Cytoprotective Functions but Minimal Anticoagulant Activity.. <i>Blood</i> , 2007, 110, 268-268.	1.4	0
172	Plasma cholesteryl ester transfer protein and blood coagulability. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1160-4.	3.4	5
173	Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis. <i>Critical Care</i> , 2006, 10, R16.	5.8	33
174	The promise of protein C. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 36, 211-216.	1.4	45
175	Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 2381.	3.0	54
176	Graft protein C entrapment is associated with reduced phagocyte activation during reperfusion in human liver transplantation. <i>Critical Care Medicine</i> , 2006, 34, 426-432.	0.9	8
177	Is adiponectin implicated in venous thromboembolism?. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1151-1152.	3.8	2
178	Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1315-1322.	3.8	40
179	Cholesteryl ester transfer protein genotypes associated with venous thrombosis and dyslipoproteinemia in males. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2080-2082.	3.8	8
180	Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates. <i>British Journal of Haematology</i> , 2006, 132, 197-203.	2.5	10

#	ARTICLE	IF	CITATIONS
181	Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. <i>Nature Medicine</i> , 2006, 12, 1278-1285.	30.7	243
182	Activated Protein C in the Cardioplegic Solution on a Porcine Model of Coronary Ischemia-Reperfusion has Deleterious Hemodynamic Effects. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 113-121.	2.6	5
183	A novel ELISA for mouse activated protein C in plasma. <i>Journal of Immunological Methods</i> , 2006, 314, 174-181.	1.4	16
184	Endothelial and Antithrombotic Actions of HDL. <i>Circulation Research</i> , 2006, 98, 1352-1364.	4.5	552
185	Protective Signaling by Activated Protein C Is Mechanistically Linked to Protein C Activation on Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 20077-20084.	3.4	120
186	Mechanisms for Mortality Reduction by Activated Protein C in Severe Sepsis.. <i>Blood</i> , 2006, 108, 1-1.	1.4	18
187	Risk of Recurrent Venous Thromboembolism Reduced by High Density Lipoproteins.. <i>Blood</i> , 2006, 108, 271-271.	1.4	4
188	Anti-Inflammatory and Anti-Apoptotic Activities of Activated Protein C Are Independent of Anticoagulant Activity.. <i>Blood</i> , 2006, 108, 65-65.	1.4	4
189	Platelet Factor 4 (PF4) Modulation of Endothelial Protein C Receptor and Thrombomodulin Enhancements of Protein C Activation and TAFI Activation by Thrombin.. <i>Blood</i> , 2006, 108, 1791-1791.	1.4	0
190	Cholesterol enhances phospholipid-dependent activated protein C anticoagulant activity. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 340-345.	3.8	2
191	Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 935-938.	3.8	26
192	Activated Protein C Reduces Graft Neutrophil Activation in Clinical Renal Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 2204-2212.	4.7	20
193	Functional recovery after embolic stroke in rodents by activated protein C. <i>Annals of Neurology</i> , 2005, 58, 474-477.	5.3	67
194	High-Density Lipoprotein Deficiency and Dyslipoproteinemia Associated With Venous Thrombosis in Men. <i>Circulation</i> , 2005, 112, 893-899.	1.6	156
195	Protective Effect of Activated Protein C in Murine Endotoxemia: Mechanism of Action.. <i>Blood</i> , 2005, 106, 26-26.	1.4	6
196	Activated Protein C Light Chain Mutations Distinguish Exosite Residue Requirements for Anticoagulant Versus Cytoprotective Activities.. <i>Blood</i> , 2005, 106, 29-29.	1.4	0
197	Efficient Barrier Protective Signaling by Activated Protein C Is Mechanistically Linked to Protein C Activation on Endothelial Cells.. <i>Blood</i> , 2005, 106, 28-28.	1.4	1
198	Sphingolipids as Bioactive Regulators of Thrombin Generation. <i>Journal of Biological Chemistry</i> , 2004, 279, 12036-12042.	3.4	46

#	ARTICLE	IF	CITATIONS
199	Activated Protein C Preserves Functional Islet Mass After Intraportal Transplantation: A Novel Link Between Endothelial Cell Activation, Thrombosis, Inflammation, and Islet Cell Death. <i>Diabetes</i> , 2004, 53, 2804-2814.	0.6	121
200	Prothrombin Residues 473-487 Contribute to Factor Va Binding in the Prothrombinase Complex. <i>Journal of Biological Chemistry</i> , 2004, 279, 49019-49025.	3.4	25
201	Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va. <i>Proteins: Structure, Function and Bioinformatics</i> , 2004, 54, 433-441.	2.6	19
202	Activated Protein C Prevents Neuronal Apoptosis via Protease Activated Receptors 1 and 3. <i>Neuron</i> , 2004, 41, 563-572.	8.1	243
203	Activated protein C and ischemic stroke. <i>Critical Care Medicine</i> , 2004, 32, S247-S253.	0.9	47
204	Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. <i>Blood</i> , 2004, 104, 1740-1744.	1.4	167
205	Factor Xa Binding Sites on Factor Va in the Prothrombinase Complex.. <i>Blood</i> , 2004, 104, 1713-1713.	1.4	0
206	Whole Blood Thromboelastogram Assays Demonstrate Prolonged Factor VIIIa Potency for Recombinant Disulfide Bond-Stabilized Factor VIII Variants.. <i>Blood</i> , 2004, 104, 2976-2976.	1.4	5
207	Targeted Replacement of the Murine Thrombomodulin Gene with Human Thrombomodulin Coding Sequence Results in Decreased Protein C Activation and Enhanced Thrombotic Response to Photochemical Injury.. <i>Blood</i> , 2004, 104, 2980-2980.	1.4	0
208	Sustained Pharmacological Activation of Protein C (PC) in Baboons.. <i>Blood</i> , 2004, 104, 3499-3499.	1.4	0
209	Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. <i>Nature Medicine</i> , 2003, 9, 338-342.	30.7	556
210	Enantiotracin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2239-2240.	2.2	7
211	Multivalent Drug Design. Synthesis and In Vitro Analysis of an Array of Vancomycin Dimers. <i>Journal of the American Chemical Society</i> , 2003, 125, 6517-6531.	13.7	72
212	Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. <i>Blood Cells, Molecules, and Diseases</i> , 2003, 30, 271-276.	1.4	71
213	Glucosylceramide, a Neutral Glycosphingolipid Anticoagulant Cofactor, Enhances the Interaction of Human- and Bovine-activated Protein C with Negatively Charged Phospholipid Vesicles. <i>Journal of Biological Chemistry</i> , 2003, 278, 14614-14621.	3.4	21
214	Protein S Confers Neuronal Protection During Ischemic/Hypoxic Injury in Mice. <i>Circulation</i> , 2003, 107, 1791-1796.	1.6	86
215	Identification of Distinct Sequences in Human Blood Coagulation Factor Xa and Prothrombin Essential for Substrate and Cofactor Recognition in the Prothrombinase Complex. <i>Journal of Biological Chemistry</i> , 2003, 278, 33312-33318.	3.4	41
216	Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7830-7835.	7.1	198

#	ARTICLE	IF	CITATIONS
217	Activation of protein C during reperfusion in clinical liver transplantation. <i>Transplantation</i> , 2003, 75, 467-472.	1.0	14
218	Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. <i>Blood</i> , 2003, 102, 146-151.	1.4	72
219	Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. <i>Blood</i> , 2003, 101, 4797-4801.	1.4	107
220	Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. <i>Biochemical Journal</i> , 2003, 373, 65-70.	3.7	219
221	Neutral Glycosphingolipid-dependent Inactivation of Coagulation Factor Va by Activated Protein C and Protein S. <i>Journal of Biological Chemistry</i> , 2002, 277, 8861-8865.	3.4	19
222	Anticoagulant Responses to Thrombin Are Enhanced During Regression of Atherosclerosis in Monkeys. <i>Circulation</i> , 2002, 106, 842-846.	1.6	22
223	Molecular Characterization of an Extended Binding Site for Coagulation Factor Va in the Positive Exosite of Activated Protein C. <i>Journal of Biological Chemistry</i> , 2002, 277, 28836-28840.	3.4	72
224	Oral anticoagulation reduces activated protein C less than protein C and other vitamin K-dependent clotting factors. <i>Blood</i> , 2002, 100, 4232-4233.	1.4	12
225	Effect of hyperhomocysteinemia on protein C activation and activity. <i>Blood</i> , 2002, 100, 2108-2112.	1.4	36
226	Conversion of a Plant Oxidosqualene-Cycloartenol Synthase to an Oxidosqualene-Lanosterol Cyclase by Random Mutagenesis. <i>Biochemistry</i> , 2002, 41, 8238-8244.	2.5	40
227	Protein C Pathway Impairment in Nonsymptomatic Cigarette Smokers. <i>Blood Cells, Molecules, and Diseases</i> , 2002, 29, 73-82.	1.4	19
228	Low Protein Z Levels and Risk of Ischemic Stroke: Differences by Diabetic Status and Gender. <i>Blood Cells, Molecules, and Diseases</i> , 2002, 29, 139-144.	1.4	58
229	Activated Protein C-Dependent and -Independent Anticoagulant Activities of Protein S Have Different Structural Requirements. <i>Blood Cells, Molecules, and Diseases</i> , 2002, 29, 190-199.	1.4	17
230	Activated protein C: Potential therapy for severe sepsis, thrombosis, and stroke. <i>Seminars in Hematology</i> , 2002, 39, 197-205.	3.4	85
231	Coagulation Pathways in Atherothrombosis. <i>Trends in Cardiovascular Medicine</i> , 2002, 12, 317-324.	4.9	23
232	Factor Va Increases the Affinity of Factor Xa for Prothrombin. <i>Chemistry and Biology</i> , 2002, 9, 485-494.	6.0	14
233	Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II. <i>British Journal of Haematology</i> , 2002, 117, 676-684.	2.5	9
234	Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. <i>Protein Science</i> , 2002, 11, 2091-2101.	7.6	45

#	ARTICLE	IF	CITATIONS
235	American College of Medical Genetics Consensus Statement on Factor V Leiden Mutation Testing. <i>Genetics in Medicine</i> , 2001, 3, 139-148.	2.4	166
236	Plasma Lipoproteins, Hemostasis and Thrombosis. <i>Thrombosis and Haemostasis</i> , 2001, 86, 386-394.	3.4	95
237	Anticoagulant Dysfunction of Human Arg352Trp-Activated Protein C Caused by Defective Factor Va Inactivation. <i>Thrombosis and Haemostasis</i> , 2001, 85, 274-279.	3.4	2
238	Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. <i>Blood</i> , 2001, 97, 1907-1914.	1.4	55
239	Activated protein C and inflammation in human myocardium after heart surgery. <i>American Journal of Hematology</i> , 2001, 67, 210-212.	4.1	16
240	Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke. <i>Circulation</i> , 2001, 103, 1799-1805.	1.6	202
241	Potent Anti- <i>Trypanosoma cruzi</i> Activities of Oxidosqualene Cyclase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1210-1215.	3.2	72
242	Plasma lipoproteins, hemostasis and thrombosis. <i>Thrombosis and Haemostasis</i> , 2001, 86, 386-94.	3.4	34
243	Conformational changes in activated protein C caused by binding of the first epidermal growth factor-like module of protein S. <i>Biochemical Journal</i> , 2000, 349, 757-764.	3.7	30
244	Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. <i>Critical Care Medicine</i> , 2000, 28, 2209-2216.	0.9	248
245	The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. <i>Blood</i> , 2000, 96, 585-593.	1.4	50
246	Causes of Thrombophilia Yet to Be Discovered: A Personal View. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000, 30, 26-33.	0.3	0
247	Three-dimensional Model of Coagulation Factor Va Bound to Activated Protein C. <i>Thrombosis and Haemostasis</i> , 2000, 84, 849-857.	3.4	66
248	Chemical synthesis and spontaneous folding of a multidomain protein: Anticoagulant microprotein S. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 14074-14078.	7.1	37
249	Cardiolipin is a normal component of human plasma lipoproteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 1743-1748.	7.1	94
250	Inactivation of Active Thrombin-activable Fibrinolysis Inhibitor Takes Place by a Process That Involves Conformational Instability Rather Than Proteolytic Cleavage. <i>Journal of Biological Chemistry</i> , 2000, 275, 12410-12415.	3.4	81
251	Cardiolipin Enhances Protein C Pathway Anticoagulant Activity. <i>Blood Cells, Molecules, and Diseases</i> , 2000, 26, 115-123.	1.4	22
252	The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. <i>Blood</i> , 2000, 96, 585-593.	1.4	22

#	ARTICLE	IF	CITATIONS
253	Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C. <i>Blood</i> , 1999, 94, 895-901.	1.4	36
254	Impaired Anticoagulant Response to Infusion of Thrombin in Atherosclerotic Monkeys Associated With Acquired Defects in the Protein C System. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1744-1750.	2.4	30
255	C-terminal Residues 621-635 of Protein S Are Essential for Binding to Factor Va. <i>Journal of Biological Chemistry</i> , 1999, 274, 36187-36192.	3.4	32
256	Tissue Plasminogen Activator (tPA) Deficiency Exacerbates Cerebrovascular Fibrin Deposition and Brain Injury in a Murine Stroke Model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2801-2806.	2.4	127
257	Cardiopulmonary bypass and activation of antithrombotic plasma protein C. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1999, 118, 422-431.	0.8	24
258	Protein synthesis by native chemical ligation: Expanded scope by using straightforward methodology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 10068-10073.	7.1	634
259	Two Multiplex PCR-Based DNA Assays for the Thrombosis Risk Factors Prothrombin G20210A and Coagulation Factor V G1691A Polymorphisms. <i>Thrombosis Research</i> , 1999, 93, 265-269.	1.7	13
260	Brain-Specific Protein C Activation During Carotid Artery Occlusion in Humans. <i>Stroke</i> , 1999, 30, 542-545.	2.0	32
261	Dermatan Sulfate and LMW Heparin Enhance the Anticoagulant Action of Activated Protein C. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1462-1468.	3.4	24
262	High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. <i>Journal of Clinical Investigation</i> , 1999, 103, 219-227.	8.2	197
263	Chemical synthesis of human protein S thrombin-sensitive module and first epidermal growth factor module. <i>Biopolymers</i> , 1998, 46, 53-63.	2.4	18
264	Synthesis and Properties of Metalloporphyrin Monolayers and Stacked Multilayers Bound to an Electrode via Site Specific Axial Ligation to a Self-Assembled Monolayer. <i>Journal of the American Chemical Society</i> , 1998, 120, 4478-4487.	13.7	160
265	Involvement of Amino Acid Residues 423-429 of Human Protein S in Binding to C4b-Binding Protein. <i>Blood Cells, Molecules, and Diseases</i> , 1998, 24, 101-112.	1.4	19
266	Homology Models of the C Domains of Blood Coagulation Factors V and VIII: A Proposed Membrane Binding Mode for FV and FVIII C2 Domains. <i>Blood Cells, Molecules, and Diseases</i> , 1998, 24, 448-461.	1.4	52
267	Inhibition of Prothrombinase by Human Secretory Phospholipase A2 Involves Binding to Factor Xa. <i>Journal of Biological Chemistry</i> , 1998, 273, 23764-23772.	3.4	48
268	Binding Site for Blood Coagulation Factor Xa Involving Residues 311-325 in Factor Va. <i>Journal of Biological Chemistry</i> , 1998, 273, 14900-14905.	3.4	35
269	Upregulation of the Antithrombotic Protein C Pathway at Birth. <i>Pediatric Hematology and Oncology</i> , 1998, 15, 489-499.	0.8	11
270	Circulating Activated Protein C in Subjects with Heterozygous Gln506-Factor V. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1998, 28, 31-36.	0.3	3

#	ARTICLE	IF	CITATIONS
271	Activated Protein C Resistance: What Have We Learned Now That the Dust Has Settled?. <i>Annals of Medicine</i> , 1997, 29, 469-472.	3.8	8
272	Potent Blood Coagulant Activity of Human Semen Due to Prostate-Bound Tissue Factor. <i>Biology of Reproduction</i> , 1997, 56, 757-763.	2.7	55
273	Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 11484-11489.	7.1	37
274	A Single Genetic Origin for a Common Caucasian Risk Factor for Venous Thrombosis. <i>Blood</i> , 1997, 89, 397-402.	1.4	246
275	Total chemical synthesis of enzymatically active human type II secretory phospholipase A2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 7845-7850.	7.1	78
276	The Carbohydrate Moiety of Factor V Modulates Inactivation by Activated Protein C. <i>Blood</i> , 1997, 89, 4348-4354.	1.4	21
277	Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. <i>Protein Science</i> , 1997, 6, 132-140.	7.6	29
278	Activated protein C correlates inversely with thrombin levels in resting healthy individuals. , 1997, 56, 29-31.		9
279	Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.. <i>Journal of Clinical Investigation</i> , 1997, 99, 2655-2663.	8.2	24
280	Novel Vancomycin Dimers with Activity against Vancomycin-Resistant Enterococci. <i>Journal of the American Chemical Society</i> , 1996, 118, 13107-13108.	13.7	139
281	Electrocatalytic Reduction of Dioxygen by Diruthenium Cofacial Diporphyrins Axially-Bound to a Gold-Supported, Self-Assembled Monolayer. <i>Inorganic Chemistry</i> , 1996, 35, 1751-1752.	4.0	42
282	Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. <i>Protein Science</i> , 1996, 5, 1883-1889.	7.6	54
283	Thrombosis in otherwise well children with the factor V Leiden mutation. <i>Journal of Pediatrics</i> , 1996, 128, 324-328.	1.8	60
284	Solid-Phase Total Synthesis of Bacitracin A. <i>Journal of Organic Chemistry</i> , 1996, 61, 3983-3986.	3.2	40
285	Resistance to Activated Protein C: A Common Inherited Cause of Venous Thrombosis. <i>Annals of Vascular Surgery</i> , 1996, 10, 174-177.	0.9	15
286	Central venous thrombosis after cardiac operations in children. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1996, 112, 883-889.	0.8	64
287	Design, synthesis and in vitro evaluation of pyridinium ion based cyclase inhibitors and antifungal agents. <i>Bioorganic and Medicinal Chemistry</i> , 1996, 4, 97-103.	3.0	20
288	Steric and Electronic Effects, Enantiospecificity, and Reactive Orientation in DNA Binding/Cleaving by Substituted Derivatives of [SalenMn(III)]+. <i>Inorganic Chemistry</i> , 1996, 35, 4837-4847.	4.0	95

#	ARTICLE	IF	CITATIONS
289	A Two-Allele Polymorphism in Protein C Inhibitor with Varying Frequencies in Different Ethnic Populations. <i>Thrombosis and Haemostasis</i> , 1996, 75, 062-069.	3.4	8
290	Impairments of the Protein C System and Fibrinolysis in Infection-Associated Stroke. <i>Stroke</i> , 1996, 27, 2005-2011.	2.0	106
291	Activated Protein C Resistance in Ischemic Stroke Not Due to Factor V Arginine <sup>506</sup> Glutamine Mutation. <i>Stroke</i> , 1996, 27, 1163-1166.	2.0	63
292	Anticoagulant response to activated protein c: Method validation and assay comparison. <i>Journal of Clinical Laboratory Analysis</i> , 1995, 9, 418-423.	2.1	0
293	The thrombin paradox. <i>Nature</i> , 1995, 378, 337-338.	27.8	117
294	Correlations among the DNA binding/cleaving specificities of small molecules revealed by double-strand affinity cleaving. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1995, 5, 73-76.	2.2	5
295	Comparative modeling of the three CP modules of the ÅŸ-chain of C4BP and evaluation of potential sites of interaction with protein S. <i>Protein Engineering, Design and Selection</i> , 1995, 8, 1253-1258.	2.1	15
296	Two Mutations in the Promoter Region of the Human Protein C Gene Both Cause Type I Protein C Deficiency by Disruption of Two HNF-3 Binding Sites. <i>Journal of Biological Chemistry</i> , 1995, 270, 24216-24221.	3.4	43
297	General and Efficient Method for the Solution- and Solid-Phase Synthesis of Vancomycin Carboxamide Derivatives. <i>Journal of Organic Chemistry</i> , 1995, 60, 1102-1103.	3.2	43
298	Alternative PCR method for diagnosis of mutation causing activated protein C resistant Gln506-factor V. <i>Thrombosis Research</i> , 1995, 80, 441-443.	1.7	16
299	Activated Protein C Resistance: Molecular Mechanisms. <i>Thrombosis and Haemostasis</i> , 1995, 74, 444-448.	3.4	73
300	Evolution of Sterol and Triterpene Cyclases. <i>ACS Symposium Series</i> , 1994, , 44-54.	0.5	6
301	Variability of Thrombosis among Homozygous Siblings with Resistance to Activated Protein C Due to an Arg-to-Gln Mutation in the Gene for Factor V. <i>New England Journal of Medicine</i> , 1994, 331, 1559-1562.	27.0	131
302	Exonic polymorphisms in the protein C gene: interethnic comparison between Caucasians and Asians. <i>Human Genetics</i> , 1994, 94, 177-8.	3.8	4
303	Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen. <i>Protein Science</i> , 1994, 3, 588-599.	7.6	39
304	A structural model for the prostate disease marker, human prostate-specific antigen. <i>Protein Science</i> , 1994, 3, 2033-2044.	7.6	71
305	Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: Patterns revealed by three-dimensional molecular modelling of mutations of the protease domain. <i>Proteins: Structure, Function and Bioinformatics</i> , 1994, 18, 367-380.	2.6	42
306	Analysis of Protein S C4b-Binding Protein Interactions by Homology Modeling and Inhibitory Antibodies. <i>Biochemistry</i> , 1994, 33, 11073-11078.	2.5	20

#	ARTICLE	IF	CITATIONS
307	Protein S binds to and inhibits factor Xa.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 2728-2732.	7.1	153
308	Possible Structural Implications of 20 Mutations in the Protein C Protease Domain. Thrombosis and Haemostasis, 1994, 72, 869-873.	3.4	5
309	Protein C inhibitor is expressed in tubular cells of human kidney.. Journal of Clinical Investigation, 1994, 94, 2117-2124.	8.2	45
310	Interactions and inhibition of blood coagulation factor Va involving residues 311â€“325 of activated protein C. Protein Science, 1993, 2, 1482-1489.	7.6	28
311	Protein S, an Antithrombotic Factor, Is Synthesized and Released by Neural Tumor Cells. Journal of Neurochemistry, 1993, 61, 344-347.	3.9	24
312	Generation of activated protein C during thrombolysis. Lancet, The, 1993, 342, 1275-1276.	13.7	25
313	Specific DNA cleavage mediated by manganese complex [SalenMn(III)]+. Journal of Organic Chemistry, 1993, 58, 820-822.	3.2	86
314	A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va. Biochemistry, 1993, 32, 12656-12663.	2.5	35
315	Evidence for the Regulation of Urokinase and Tissue Type Plasminogen Activators by the Serpin, Protein C Inhibitor, in Semen and Blood Plasma. Thrombosis and Haemostasis, 1993, 70, 0989-0994.	3.4	52
316	High molecular weight kininogen receptor. Methods in Enzymology, 1992, 215, 369-382.	1.0	4
317	Nucleotide and deduced amino acid sequences of the oxidosqualene cyclase from Candida albicans. Journal of the American Chemical Society, 1992, 114, 9711-9713.	13.7	82
318	The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. FEBS Journal, 1992, 208, 171-178.	0.2	67
319	Complexes of activated protein C with $\alpha_1$ -antitrypsin in normal pregnancy and in severe preeclampsia. American Journal of Obstetrics and Gynecology, 1991, 164, 1310-1316.	1.3	25
320	Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates.. Circulation, 1991, 84, 2454-2462.	1.6	67
321	Interaction of Plasma Kallikrein with Protein C Inhibitor in Purified Mixtures and in Plasma. Thrombosis and Haemostasis, 1991, 65, 046-051.	3.4	20
322	Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis.. Circulation, 1990, 82, 578-585.	1.6	130
323	Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8506-8510.	7.1	65
324	Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thrombosis Research, 1990, 59, 593-608.	1.7	78

#	ARTICLE	IF	CITATIONS
325	Purification and characterization of plasma protein C inhibitor. <i>Thrombosis Research</i> , 1989, 55, 369-384.	1.7	95
326	Aprotinin (Trasylol) is a competitive inhibitor of activated protein C. <i>Thrombosis Research</i> , 1989, 56, 751-756.	1.7	69
327	Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISA's. <i>Thrombosis Research</i> , 1989, 55, 671-682.	1.7	52
328	Functional Assays for Protein C Activity and Protein C Inhibitor Activity in Plasma. <i>Thrombosis and Haemostasis</i> , 1989, 61, 086-092.	3.4	10
329	Immunoblotting studies of the molecular forms of protein C in plasma. <i>Thrombosis Research</i> , 1988, 52, 33-43.	1.7	61
330	Competition of activated protein C and urokinase for a heparinâ€dependent inhibitor 1. <i>FASEB Journal</i> , 1988, 2, 2263-2267.	0.5	13
331	Detection and Quantitation of Cleaved and Uncleaved High Molecular Weight Kininogen in Plasma by Ligand Blotting with Radiolabeled Plasma Prekallikrein or Factor XI. <i>Thrombosis and Haemostasis</i> , 1988, 59, 151-161.	3.4	33
332	Immunoblotting Studies of Coagulation Factor XII, Plasma Prekallikrein, and High Molecular Weight Kininogen. <i>Seminars in Thrombosis and Hemostasis</i> , 1987, 13, 106-114.	2.7	13
333	Sulfatide bilayers as a surface for contact activation in human plasma. <i>Biochemical and Biophysical Research Communications</i> , 1987, 149, 1002-1007.	2.1	7
334	Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa. <i>FEBS Journal</i> , 1987, 164, 637-642.	0.2	42
335	Binding of coagulation factor XI to washed human platelets. <i>Biochemistry</i> , 1986, 25, 3884-3890.	2.5	105
336	Effect of l-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. <i>Journal of Pediatrics</i> , 1986, 108, 698-701.	1.8	45
337	Chapter 5A Initiation mechanisms: The contact activation system in plasma. <i>New Comprehensive Biochemistry</i> , 1986, , 103-128.	0.1	4
338	Enhanced specificity of immunoblotting using radiolabeled antigen overlay: Studies of blood coagulation factor XII and prekallikrein in plasma. <i>Analytical Biochemistry</i> , 1986, 156, 118-125.	2.4	30
339	Effects of subperineurial injections of very-long-chain and medium-chain fatty acids into rat sciatic nerve. <i>Neurochemical Pathology</i> , 1986, 5, 71-83.	1.1	3
340	Quantitative Immunoblotting of Plasma and Platelet Protein S. <i>Thrombosis and Haemostasis</i> , 1986, 56, 382-386.	3.4	17
341	Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency.. <i>Journal of Clinical Investigation</i> , 1986, 78, 170-176.	8.2	18
342	The Function of the Heavy and Light Chain of Human Plasma Kallikrein in the Activation of Factor XII. <i>Advances in Experimental Medicine and Biology</i> , 1986, 198 Pt B, 27-34.	1.6	1

#	ARTICLE	IF	CITATIONS
343	Surface-dependent activation of human factor XII (Hageman factor) by Kallikrein and its light chain. FEBS Journal, 1985, 151, 531-538.	0.2	32
344	The effect of trypsin from human mast cells on human prekallikrein. Biochemical and Biophysical Research Communications, 1985, 129, 76-81.	2.1	19
345	Formation of the Fibrin Clot: the Balance of Procoagulant and Inhibitory Factors. Clinics in Haematology, 1985, 14, 281-342.	2.3	51
346	A Protein S Deficient Family with Portal Vein Thrombosis. Thrombosis and Haemostasis, 1985, 54, 724-724.	3.4	36
347	Clinical Studies of Protein C. Seminars in Thrombosis and Hemostasis, 1984, 10, 162-166.	2.7	69
348	Receptors for high molecular weight kininogen on stimulated washed human platelets. Biochemistry, 1984, 23, 6863-6869.	2.5	114
349	Studies on human protein C inhibitor in normal and factor V/VIII deficient plasmas. Thrombosis Research, 1984, 36, 197-203.	1.7	21
350	Overview on Blood Coagulation Proteins. , 1984, , 39-55.		0
351	Interaction of human plasma kallikrein and its light chain with C.hivin.1 inhibitor. Biochemistry, 1983, 22, 4860-4866.	2.5	45
352	A comparison of the abilities of plasma kallikrein, $\hat{I}^2$ -factor XIIa, factor XIa and urokinase to activate plasminogen. Thrombosis Research, 1983, 29, 407-417.	1.7	90
353	MECHANISMS FOR THE CONVERSION OF BLOOD COAGULATION PROENZYMES TO ENZYMES. , 1983, , 201-224.		0
354	The Biochemistry and Pathophysiology of the Contact System of Plasma. Advances in Immunology, 1982, 33, 241-306.	2.2	132
355	PLATELET-COAGULANT PROTEIN INTERACTIONS IN CONTACT ACTIVATION*. Annals of the New York Academy of Sciences, 1981, 370, 241-252.	3.8	14
356	HUMAN PROTEIN C: INACTIVATION OF FACTORS V AND VIII IN PLASMA BY THE ACTIVATED MOLECULE*. Annals of the New York Academy of Sciences, 1981, 370, 303-310.	3.8	73
357	ALTERNATIVE PATHWAYS OF THROMBOPLASTIN-DEPENDENT ACTIVATION OF HUMAN FACTOR X IN PLASMA*. Annals of the New York Academy of Sciences, 1981, 370, 325-335.	3.8	14
358	Deficiency of protein C in congenital thrombotic disease.. Journal of Clinical Investigation, 1981, 68, 1370-1373.	8.2	1,130
359	Activation of Rabbit Hageman Factor by Homogenates of Cultured Rabbit Endothelial Cells. Journal of Clinical Investigation, 1980, 65, 197-206.	8.2	71
360	Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry, 1980, 19, 1151-1160.	2.5	107

#	ARTICLE	IF	CITATIONS
361	Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease.. Journal of Clinical Investigation, 1980, 66, 1186-1189.	8.2	191
362	Recent Advances in The Understanding of Contact Activation Reactions. Seminars in Thrombosis and Hemostasis, 1979, 5, 254-273.	2.7	121
363	Molecular assembly in the contact phase of the Hageman factor system. American Journal of Medicine, 1979, 67, 657-664.	1.5	76
364	Rabbit blood coagulation factor XI. Purification and properties. Thrombosis Research, 1979, 15, 475-486.	1.7	21
365	Rabbit blood coagulation factor XI. Mechanism of activation by rabbit Hageman factor (factor XII). Thrombosis Research, 1979, 15, 487-495.	1.7	10
366	Activation of Human Factor VII in Plasma and in Purified Systems. Journal of Clinical Investigation, 1979, 64, 1056-1065.	8.2	148
367	Circulating inhibitors of blood coagulation associated with procainamide-induced lupus erythematosus. American Journal of Hematology, 1978, 4, 401-407.	4.1	22
368	Evidence for the participation of both activated factor XII and activated factor IX in cold-promoted activation of factor VII. Thrombosis Research, 1978, 13, 1049-1056.	1.7	37
369	Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma.. Journal of Experimental Medicine, 1978, 147, 719-729.	8.5	150
370	Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII). Proceedings of the National Academy of Sciences of the United States of America, 1978, 75, 1998-2002.	7.1	225
371	The Binding and Cleavage Characteristics of Human Hageman Factor during Contact Activation. Journal of Clinical Investigation, 1977, 59, 1167-1175.	8.2	150
372	Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.. Proceedings of the National Academy of Sciences of the United States of America, 1977, 74, 4636-4640.	7.1	174
373	<sup>13</sup> C nuclear magnetic resonance studies of the binding of selectively <sup>13</sup> C -enriched oxytocins to the neurohypophyseal protein, bovine neurophysin II. Biochemistry, 1977, 16, 4194-4198.	2.5	19
374	Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor.. Proceedings of the National Academy of Sciences of the United States of America, 1976, 73, 2554-2558.	7.1	267
375	[7] Human factor XII (Hageman factor). Methods in Enzymology, 1976, 45, 56-65.	1.0	109
376	STUDIES OF BOVINE NEUROPHYSIN-NEUROHYPOPHYSEAL HORMONE INTERACTIONS. Annals of the New York Academy of Sciences, 1975, 248, 463-479.	3.8	19
377	Drug-Biomolecule Interactions: Proton Magnetic Resonance Studies of Complex Formation between Bovine Neurophysins and Oxytocin at Molecular Level. Journal of Pharmaceutical Sciences, 1975, 64, 507-511.	3.3	6
378	Application of nuclear magnetic resonance spectroscopy to proteins. Biochimie, 1975, 57, 453-460.	2.6	3

#	ARTICLE	IF	CITATIONS
379	Carbon-13 nuclear magnetic resonance studies on (85% <sup>13</sup> C-enriched Gly9 ) oxytocin. FEBS Letters, 1975, 50, 168-171.	2.8	19
380	Interactions of Bovine Neurophysin II with Oxytocin and [8-Lysine] Vasopressin. Journal of Biological Chemistry, 1974, 249, 6895-6900.	3.4	22
381	NUCLEAR MAGNETIC RESONANCE STUDIES OF A RIBONUCLEASE-DINUCLEOSIDE PHOSPHONATE COMPLEX AND THEIR IMPLICATIONS FOR THE MECHANISM OF THE ENZYME. Annals of the New York Academy of Sciences, 1973, 222, 693-708.	3.8	39
382	Assignment of an exchangeable low-field nitrogen-hydrogen proton resonance of ribonuclease A to the active-site histidine-119. Biochemistry, 1973, 12, 2096-2099.	2.5	28
383	Complex Formation between Bovine Neurophysin-I and Oxytocin, Vasopressin, and Tripeptide Analogs of Their NH <sub>2</sub> -terminal Region. Journal of Biological Chemistry, 1973, 248, 7975-7978.	3.4	34
384	Hormonal interactions at the molecular level: A high resolution proton magnetic resonance study of bovine neurophysins and their interactions with oxytocin. FEBS Letters, 1972, 25, 282-286.	2.8	28